NLA scientific statement on statin intolerance: a new definition and key considerations for ASCVD risk reduction in the statin intolerant patient

医学 他汀类 不利影响 中止 重症监护医学 内科学 物理疗法
作者
Mary Katherine Cheeley,Joseph J. Saseen,Anandita Agarwala,Sudha Ravilla,Nicole A. Ciffone,Terry A. Jacobson,Dave L. Dixon,Kevin Carl Maki
出处
期刊:Journal of Clinical Lipidology [Elsevier BV]
卷期号:16 (4): 361-375 被引量:210
标识
DOI:10.1016/j.jacl.2022.05.068
摘要

Although statins are generally well tolerated, statin intolerance is reported in 5-30% of patients and contributes to reduced statin adherence and persistence, as well as higher risk for adverse cardiovascular outcomes. This Scientific Statement from the National Lipid Association was developed to provide an updated definition of statin intolerance and to inform clinicians and researchers about its identification and management. Statin intolerance is defined as one or more adverse effects associated with statin therapy which resolves or improves with dose reduction or discontinuation and can be classified as a complete inability to tolerate any dose of a statin or partial intolerance with inability to tolerate the dose necessary to achieve the patient-specific therapeutic objective. To classify a patient as having statin intolerance, a minimum of two statins should have been attempted, including at least one at the lowest approved daily dosage. This Statement acknowledges the importance of identifying modifiable risk factors for statin intolerance and recognizes the possibility of a "nocebo" effect (patient expectation of harm resulting in perceived side effects). To identify a tolerable statin regimen it is recommended that clinicians consider using several different strategies (e.g., different statin, dose, and/or dosing frequency). Non-statin therapy may be required for patients who cannot reach therapeutic objectives with lifestyle and maximal tolerated statin therapy. If so, therapies with outcomes data from randomized trials showing reduced cardiovascular events are favored. In high and very high risk patients who are statin intolerant, clinicians should consider initiating non-statin therapy while additional attempts are made to identify a tolerable statin in order to limit the time of exposure to elevated levels of atherogenic lipoproteins.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
科研通AI6.4的应助被筑梦之鱼采纳,获得10
刚刚
wxwx发布了新的文献求助10
1秒前
加油完成签到 ,获得积分10
3秒前
3秒前
4秒前
4秒前
6秒前
qiqi发布了新的文献求助10
7秒前
7秒前
wanci的应助被小小怪采纳,获得10
7秒前
wangbw发布了新的文献求助10
7秒前
8秒前
Pupupapa完成签到,获得积分20
8秒前
lulu完成签到,获得积分10
9秒前
Bai发布了新的文献求助10
9秒前
Akim的应助被blinkals57采纳,获得10
9秒前
ui24发布了新的文献求助10
9秒前
9秒前
淡定访琴完成签到,获得积分10
10秒前
搜集达人的应助被mhx1234567890采纳,获得10
11秒前
13秒前
孤独的凤完成签到,获得积分10
13秒前
14秒前
14秒前
音阙发布了新的文献求助10
14秒前
Sxya发布了新的文献求助30
15秒前
dingyushu完成签到,获得积分10
15秒前
秋风的应助被pinkstar采纳,获得10
15秒前
科研通AI6.3的应助被向星采纳,获得10
16秒前
16秒前
16秒前
dkfsgeicn完成签到,获得积分10
17秒前
情怀的应助被ZYH采纳,获得10
17秒前
18秒前
orixero的应助被Kevin采纳,获得10
18秒前
phoebe发布了新的文献求助10
19秒前
研友_VZG7GZ的应助被香辣牛排采纳,获得10
19秒前
19秒前
20秒前
2dingyushu完成签到,获得积分10
20秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8178807
求助须知:如何正确求助?哪些是违规求助? 9569558
关于积分的说明 21805222
捐赠科研通 7773974
什么是DOI,文献DOI怎么找? 3432933
关于科研通互助平台的介绍 2556873
邀请新用户注册赠送积分活动 2478593